← Markets

CareDx, Inc

CDNA · NASDAQ

Market closed$39.73$-0.610000 (-1.51%)After hours $39.88 · +0.38%

Key statistics

Previous close$40.34
Open$37.91
Day high$40.47
Day low$37.74
52-week high$40.47
52-week low$11.26
Market cap2.05B
Volume1.76M
Average volume878.43K
P/E ratio47.30
Forward P/E—
EPS0.84
Dividend yield0.00%

Market context

Why it moved

Despite a strong rally the previous day driven by Medicare finalizing its Local Coverage Determination for CareDx's solid organ transplant molecular testing portfolio, the stock pulled back modestly as significant insider selling by the CEO and other executives — combined with analyst concerns that the share price had already run ahead of its fundamental fair value — dampened investor enthusiasm.

MarketbeatYahoo FinancePlosOupDefirate

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026CareDx shares pulled back after surging over 30% the prior session following Medicare's finalization of the Local Coverage Determination (LCD) for solid organ transplant molecular testing, which affirmed coverage for its AlloSure Kidney, AlloSure/AlloMap Heart, and AlloSure Lung surveillance portfolios. The giveback was amplified by notable insider selling disclosed after the close — CEO John Hanna sold ~118,000 shares worth over $4.4 million and Director Hannah Valantine sold ~29,000 shares worth ~$1 million on July 16 — raising some investor concern despite the company's Q2 earnings call scheduled for July 30.

-1.5121

July 17, 2026CareDx surged over 35% — its biggest single-day move in recent memory — after Medicare finalized its Local Coverage Determination (LCD) affirming coverage across the company's transplant surveillance portfolio in kidney, heart, and lung. The final policy, set to take effect August 30, resolves a key reimbursement overhang and confirms continued coverage for AlloSure Kidney, AlloSure/AlloMap Heart, and AlloSure Lung surveillance testing. BTIG analyst Mark Massaro responded by raising his price target from $28 to $45, maintaining a Buy rating. The ruling removes significant uncertainty that had weighed on shares, as coverage limits align closely with current patient utilization averages, suggesting minimal disruption to CareDx's revenue base.

35.5966

July 14, 2026CareDx edged modestly higher, supported by ongoing investor interest following a series of transformative corporate actions. The company recently completed the acquisition of Naveris — adding the NavDx blood-based test for HPV-driven cancers — and finalized the $171.7M sale of its Lab Products division to Eurobio Scientific, sharpening its focus on U.S. Precision Medicine Testing and Patient & Digital Solutions. Analysts lifted their price target to $27.80 from $25.80, citing the expanded ~$12B addressable market across transplant, specialty oncology, and cell therapy, though some valuation models still flag the stock as modestly stretched near current levels.

0.5911

July 14, 2026CareDx edged higher, modestly outperforming a broader market that closed lower amid U.S.-Iran tensions and surging oil prices. The company's transplant diagnostics franchise continues to draw investor attention following a ~69% run over the past three months, driven by significant reimbursement progress including expanded payer coverage, new covered lives, and a unique CPT code for AlloSure that supports higher average selling prices. However, a valuation analysis pegged fair value at $25.80—roughly 10% below the current price—highlighting growing debate over whether the recent reimbursement-driven re-rating has left shares fully priced.

0.8769

July 7, 2026CareDx closed down sharply after announcing a significant strategic pivot: the company sold its lab products business for $171.7M and simultaneously acquired Naveris for $161.8M plus milestones, adding NavDx MRD oncology testing and expanding its addressable market to approximately $12B. A Seeking Alpha analysis framed CareDx as an evolving specialty diagnostics compounder leveraging repeat-testing and longitudinal transplant data, while routine CEO share withholding for RSU tax obligations was also filed. The decline came amid a broader down day for U.S. equities, though the healthcare sector (XLV) remains near its 52-week high amid a notable rotation into defensive healthcare names.

-2.5809

July 2, 2026CareDx rose over 2.6%, approaching its 52-week high, as the company executed a significant strategic repositioning with two major transactions closing in quick succession. CareDx completed the $171.2M sale of its Lab Products business to Eurobio Scientific, sharpening focus on its core U.S. precision medicine testing and digital solutions, while simultaneously closing its acquisition of Naveris — whose NavDx test is the only Medicare-covered MRD test for HPV-positive Head & Neck and Anal Cancers. The Naveris deal, which generated ~$35M in revenue in 2025 (more than doubling year-over-year), expands CareDx's total addressable market to over $12 billion across transplant, specialty oncology, and cell therapy.

2.6316

June 30, 2026CareDx closed the $171.2M sale of its Lab Products business to Eurobio Scientific, a strategic divestiture that sharpens its focus on core U.S. Precision Medicine Testing Services and Patient & Digital Solutions, including expansion into specialty oncology. Shares declined despite the deal's completion, with CEO John Hanna touting a simplified operating model and disciplined capital allocation, while an insider Form 144 filing revealed CEO Hanna's intent to sell 39,500 shares via option exercise — a routine but notable disclosure on the same day as the transaction close.

-2.6639

June 26, 2026CareDx surged to a fresh 52-week high of $28.41 during the session, closing up nearly 2.65% with above-average volume nearly double its typical daily turnover, as the stock continued to build on momentum from mid-June's AlloSure Registry data release and nephrology journal publication. The company's strong fundamental backdrop — including Q1 revenue growth of 39% year-over-year, raised full-year 2026 guidance of $447–$465M, and the dismissal of a qui tam lawsuit with no monetary payment — has supported a broader re-rating, with shares up over 46% in the past three months. Broader healthcare diagnostics peers also saw positive analyst coverage, while the healthcare sector held relatively firm amid a broader tech-led market pullback this week.

2.6539

Simply Wall Street · July 19, 2026CareDx (CDNA) Is Up 39.4% After Final Medicare Coverage Clarifies Transplant Test Reimbursement LimitsTimothy Sykes · July 16, 2026CareDx (CDNA) Jumps As Naveris Deal Redraws Growth MapBusiness Wire · July 16, 2026CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026Stock Titan · July 16, 2026Medicare Policy Is Expected to Cover Up to 12 Tests After TransplantStock Titan · June 30, 2026CareDx sells Lab Products business for $171.2M, refocuses on transplant testingBusiness Wire · April 28, 2026CareDx Announces First Quarter 2026 Financial ResultsInvestor's Business Daily · April 16, 2026Why These Medical Plays Just Diverged; One Eyes A Breakout
Mt Newswire · July 17, 2026Caredx Insider Sold Shares Worth $1,040,243, According to a Recent SEC Filing
Mt Newswire · July 17, 2026Caredx Insider Sold Shares Worth $4,458,637, According to a Recent SEC Filing
Mt Newswire · July 16, 2026CareDx Shares Rise After Surveillance Testing Coverage Affirmed
Benzinga · July 16, 2026Why Is CareDx Stock Skyrocketing Thursday?
Benzinga · July 16, 2026BTIG Maintains Buy on CareDx, Raises Price Target to $45
Benzinga · July 16, 2026CareDx Finalizes Medicare Local Coverage Determination Procedure Regarding Molecular Testing For Solid Organ Allograft Rejection
Mt Newswire · July 1, 2026CareDx Closes Naveris Acquisition
Mt Newswire · June 30, 2026CareDx Closes Sale of Lab Products Business to Eurobio Scientific

Peers

S&P 500SPX · $7,457.69-1.01%Natera, Inc.NTRA · $271.39+0.58%BillionToOne, Inc.BLLN · $130.31+1.66%NeoGenomics, Inc.NEO · $14.61-1.55%Sotera Health CompanySHC · $17.75-2.85%RadNet, Inc.RDNT · $62.19-1.27%Celcuity Inc.CELC · $88.38+0.10%Caris Life Sciences, Inc.CAI · $16.49+0.06%ProKidney Corp.PROK · $1.62+0.62%Ardelyx, Inc.ARDX · $5.20+1.46%Akebia Therapeutics, Inc.AKBA · $1.34-4.29%Praxis Precision Medicines, Inc.PRAX · $314.41+2.01%